Altimmune Sells Liver Disease Business for $75M

TL;DR

Altimmune selling liver disease assets for $75M upfront to focus on obesity drugs.

AI Summary

Altimmune, Inc. announced on November 15, 2024, that it has entered into a definitive agreement to sell its liver disease business, including its NASH and NASH-related liver disease programs, to an undisclosed buyer for an upfront payment of $75 million. The transaction also includes potential milestone payments and royalties, with the sale expected to close in the first quarter of 2025.

Why It Matters

This divestiture allows Altimmune to focus on its obesity and liver failure programs, potentially streamlining its operations and concentrating resources on its most promising drug candidates.

Risk Assessment

Risk Level: medium — The sale involves an undisclosed buyer and potential future milestone payments, introducing uncertainty regarding the full value realization and the success of the remaining business segments.

Key Numbers

• $75M — Upfront Payment (Received by Altimmune for the sale of its liver disease business.)
• Q1 2025 — Expected Closing (Anticipated timeframe for the completion of the liver disease business sale.)

Key Players & Entities

• Altimmune, Inc. (company) — Seller of liver disease business
• November 15, 2024 (date) — Date of definitive agreement
• $75 million (dollar_amount) — Upfront payment for liver disease business
• first quarter of 2025 (date) — Expected closing date of the transaction

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Mar

Filing Documents

• alt-20241115x8k.htm (8-K) — 38KB
• 0001326190-24-000053.txt ( ) — 174KB
• alt-20241115.xsd (EX-101.SCH) — 3KB
• alt-20241115_lab.xml (EX-101.LAB) — 18KB
• alt-20241115_pre.xml (EX-101.PRE) — 13KB
• alt-20241115x8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events On November 15, 2024, Altimmune, Inc. presented data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting of the American Association for the Study of Liver Diseases. The data were derived from an analysis of plasma samples from subjects who completed a randomized placebo-controlled Phase 1b trial of pemvidutide in subjects with overweight or obesity and MASLD. In the Phase 1b clinical trial, 94 subjects with obesity or overweight and liver fat content (LFC) greater than or equal to 10% were dosed 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. In this study, pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTIMMUNE, INC. By: /s/ Gregory Weaver Name: Gregory Weaver Title: Chief Financial Officer Dated: December 11, 2024

View Full Filing

View this 8-K filing on SEC EDGAR